Central Laboratory, The Fifth People's Hospital of Shanghai Fudan University, Shanghai 200000, China.
Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai 200000, China.
Math Biosci Eng. 2019 Sep 26;17(1):92-104. doi: 10.3934/mbe.2020005.
: Triple-negative breast cancer (TNBC) is a subtype of breast cancer with stronger invasive capacity. For the operation strategies of early staged (stage I and stage II) TNBC patients, BCS plus radiotherapy (BCS+RT), mastectomy only (MRM only) or MRM plus radiotherapy (MRM+RT) is feasible, but no clear conclusion has been made on the choice of these treatments. : The early staged TNBC patients (stage I and stage II) from the Surveillance, Epidemiology and End Results (SEER) program database between 1973 and 2014 were included in the study. Survival curves, univariate and multivariate cox proportional hazards models and propensity score weighting were applied to evaluate the prognostic impact among BCS+RT, MRM only and MRM+RT for patients. : Both overall and cancer-specific survival analysis showed that BCS+RT had better prognostic effect than MRM and MRM+RT in the cohort of early-staged triple-negative breast cancer patients (overall survival, < 0.001; cancer-specific survival, < 0.001). By taking all the risk factors into a multivariate cox proportional model, MRM and MRM+RT remained to have detrimental effect on the prognosis compared with BCS+RT as shown by either overall (HR = 1.742, CI = 1.387-2.188, < 0.001; HR = 1.449, CI = 1.038-2.204, = 0.029) or cancer-specific survival (HR = 1.876, CI = 1.415-2.489, < 0.001; HR = 1.701, CI = 1.168-2.478, = 0.006). After we performed propensity score weighting and integrated the weights for each covariate in the multivariate cox proportional model. BCS+RT remained to be prognostic beneficial compared to the other treatment options ( < 0.001). : BCS+RT demonstrated better prognosis than MRM only and MRM+RT treatments for early-staged TNBC patients.
三阴性乳腺癌(TNBC)是一种侵袭性较强的乳腺癌亚型。对于早期(I 期和 II 期)TNBC 患者的手术策略,保乳手术加放疗(BCS+RT)、单纯乳房切除术(MRM 仅)或 MRM 加放疗(MRM+RT)都是可行的,但对于这些治疗方法的选择尚无明确结论。
本研究纳入了 1973 年至 2014 年间来自监测、流行病学和最终结果(SEER)计划数据库的早期 TNBC 患者(I 期和 II 期)。生存曲线、单变量和多变量 cox 比例风险模型以及倾向评分加权用于评估 BCS+RT、MRM 仅和 MRM+RT 三种治疗方案在患者中的预后影响。
总体和癌症特异性生存分析均表明,在早期 TNBC 患者队列中,BCS+RT 的预后优于 MRM 和 MRM+RT(总体生存,<0.001;癌症特异性生存,<0.001)。通过将所有风险因素纳入多变量 cox 比例模型,MRM 和 MRM+RT 与 BCS+RT 相比仍对预后产生不利影响,无论是总体生存(HR=1.742,CI=1.387-2.188,<0.001;HR=1.449,CI=1.038-2.204,=0.029)还是癌症特异性生存(HR=1.876,CI=1.415-2.489,<0.001;HR=1.701,CI=1.168-2.478,=0.006)。在我们进行倾向评分加权并将多变量 cox 比例模型中每个协变量的权重进行整合后,BCS+RT 与其他治疗选择相比仍然具有预后获益(<0.001)。
BCS+RT 为早期 TNBC 患者提供了比 MRM 仅和 MRM+RT 治疗更好的预后。